Senator Baldwin

American Shrimp Processors Association Applauds Affirmative Preliminary Vote on New Trade Petitions, Supports New Senate Bill to Redistribute Tariff Revenue to Affected Communities

Retrieved on: 
Friday, December 8, 2023
Tammy Baldwin, Senator Baldwin, Commerce, Resilience, ITC, ASPA

As a result of today's vote, the antidumping and countervailing duty investigations will proceed at both the ITC and the U.S.  Department of Commerce (Commerce).

Key Points: 
  • As a result of today's vote, the antidumping and countervailing duty investigations will proceed at both the ITC and the U.S.  Department of Commerce (Commerce).
  • The Act would re-direct hundreds of millions of dollars of antidumping and countervailing duty tariff revenue to the communities that are directly harmed by unfair trade.
  • "This bill could make a huge difference for the domestic shrimp industry, which has been fighting unfairly traded imports for almost twenty years.
  • We thank Senators Baldwin and Cassidy for introducing the Resilient Communities Act, and we look forward to working with them to secure its passage."

NORD Applauds Legislative Efforts to Restore Intent of the Orphan Drug Act

Retrieved on: 
Thursday, May 12, 2022
Disease, Population, Policy, Food, Multimedia, Patient, United States House Committee on Energy and Commerce, Language, Cystic fibrosis, House, Degenerative disease, Fabry disease, RARE, United States Court of Appeals for the Eleventh Circuit, Interstate Commerce Committee, Legislation, Research, Orphan drug, FDA, Orphan Drug Act of 1983, National Organization for Rare Disorders, Court, United States House Energy Subcommittee on Health, NORD, Congress, Safety, Drug development, Head, Mutation, Senate, ODA, Catalysis, Glycogen storage disease, Senator Baldwin, CEO, Pharmaceutical industry

WASHINGTON, May 11, 2022 /PRNewswire/ -- The National Organization for Rare Disorders (NORD) applauds efforts of Congressional leaders to protect the Orphan Drug Act (ODA) and ensure proper incentives are in place to continue to foster robust rare disease drug development.

Key Points: 
  • WASHINGTON, May 11, 2022 /PRNewswire/ -- The National Organization for Rare Disorders (NORD) applauds efforts of Congressional leaders to protect the Orphan Drug Act (ODA) and ensure proper incentives are in place to continue to foster robust rare disease drug development.
  • This clarification will maintain appropriate incentives to encourage rare disease drug development as intended in the Orphan Drug Act with a goal of addressing the still significant unmet needs of many in the rare disease community."
  • The Court instead held that the rare disease designated at the outset of the drug development process dictates the scope of the orphan drug exclusivity.
  • NORD began as a small group of patient advocates that formed a coalition to unify and mobilize support to pass the Orphan Drug Act of 1983.